NEUSTAR
16.9.2020 09:32:11 CEST | Business Wire | Press release
Neustar, Inc. , a global information services and technology company and leader in identity resolution, today released its latest cyberthreats and trends report which identifies significant shifts in distributed denial-of-service (DDoS) attack patterns in the first half of 2020. Neustar’s Security Operations Centre (SOC) saw a 151% increase in the number of DDoS attacks compared to the same period in 2019. These included the largest and longest attacks that Neustar has ever mitigated at 1.17 Terabits-per-second (Tbps) and 5 days and 18 hours respectively. These figures are representative of the growing number, volume and intensity of network-type cyberattacks as organisations shifted to remote operations and workers’ reliance on the internet increased.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005046/en/
Neustar’s role in providing navigation for internet requests (via its global UltraDNS network) and in detecting and mitigating threats (through its UltraDDoS Protect service) has given the company a front-row seat from which to observe macro cyberattack trends, as detailed in its CyberThreats and Trends Report: Jan-Jun 2020.
Largest and smallest DDoS attacks becoming increasingly intense and sophisticated
Large DDoS attacks are bigger, more intense, and happening in greater numbers than ever before. There has been a noticeable spike in large attacks across the industry, most notably the 2.3 Tbps attack targeting an Amazon Web Services client in February – the largest volumetric DDoS attack on record.
Neustar saw the total number of attacks increase by over two and a half times during January through June of 2020 compared to the same period in 2019. The increase was felt across all size categories, with the biggest growth happening at opposite ends of the scale – the number of attacks sized 100 Gbps and above grew a whopping 275% and the number of very small attacks, sized 5 Gbps and below, increased by more than 200%. Overall, small attacks sized 5 Gbps and below represented 70% of all attacks mitigated by Neustar between January and June of 2020.
“While large volumetric attacks capture attention and headlines, bad actors increasingly recognise the value of striking at low enough volume to bypass the traffic thresholds that would trigger mitigation to degrade performance or precision target vulnerable infrastructure like a VPN,” said Michael Kaczmarek, Neustar Vice President of Security Products. “These shifts put every organisation with an internet presence at risk of a DDoS attack – a threat that is particularly critical with global workforces reliant on VPNs for remote login. VPN servers are often left vulnerable, making it simple for cybercriminals to take an entire workforce offline with a targeted DDoS attack."
The rise in smaller DDoS attacks has been matched by increases in attack sophistication and intensity. 52% of threats mitigated by Neustar leveraged three vectors or more, with the number of attacks featuring a single vector essentially nonexistent. Neustar also tracked new amplification methods and attacks of higher intensity targeted at critical pieces of web infrastructure. The previous high-water mark of 500 millions-of-packets-per-second (Mpps) was topped this year, with an attack of over 800 Mpps recorded.
“The dependency and growth in online communications since COVID-19 has fundamentally changed what organisations must do to succeed,” said Brian McCann, President, Neustar Security Solutions. “There is no one-size-fits-all solution for security, but having a reliable cloud service that ensures availability and security for all services and users has proven to be a critical difference between barely surviving and thriving in this rapidly changing environment.”
Ongoing impact of COVID-19 on cyberthreats and industry web traffic
The precipitous rise in DDoS attacks mirrors the growth in internet traffic seen during the pandemic. Internet use is up between 50% and 70% and streaming media rose more than 12% in the first quarter of 2020 . This has meant that attackers of all types, whether serious cybercriminals or bored teenagers stuck at home, have had more screen time to be disruptive.
In a study of one of the largest cybercrime sites by Cambridge University’s Cybercrime Centre , they found that the number of attacks enacted by the website went up sharply at the start of the pandemic and associated lockdown. They also found that instead of existing cybercriminals staging more attacks, it was new attackers driving the increase in DDoS attacks.
The corresponding attacks, like internet traffic, have not been evenly spread across all websites. It’s well known that ecommerce and gaming websites have received a lot of negative attention from hackers, but there are other industries that have been hit hard by cybercriminals over the last six months. Healthcare organisations contain sensitive patient information and a growing number of IoT devices that are easily exploited. Combined with the additional pressure of the pandemic, hospitals have become some of the most desirable targets for cybercriminals. Industries that have seen a lot of growth during the pandemic, like online gambling, have also been ripe for cyberthreats. Most notably, online video has seen an incredible rise in both usage and DDoS attacks. Omdia has reported an additional 200 billion hours of Netflix viewing or Zoom video calls over initial 2020 forecasts. Where traffic rises, so too do attacks; Neustar attack mitigations for this vertical increased by 461% over the last six months.
“While 2020 has brought radical changes in behaviour to consumers and criminals alike, it is naïve to assume that actions of either audience will revert completely to pre-pandemic norms after this crisis passes,” added Kaczmarek. “Mitigating these increasingly sophisticated DDoS attacks will continue to be a necessary part of doing business online. At a time when many organisations could do with less worry, fully managed services can take the pressure off and ensure critical digital assets are safe and secure.”
The report highlights several emerging attacker tactics seen across the industry, including an increase in burst and pulse DDoS attacks, broadening abuse of built-in network protocols such as ARMS, WS-DD, CoAP and Jenkins to launch DDoS amplification attacks that can be carried out with limited resources and cause significant disruptions, NXNS attacks targeting DNS servers, RangeAmp attacks targeting Content Delivery Networks (CDNs), and a resurgence of Marai-like malware capable of building large botnets through the exploitation of poorly secured IoT devices.
A complimentary copy of Neustar’s CyberThreats and Trends Report 1H 2020 is available here .
-ENDS-
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
